The International Online Journal of Cancer & Therapeutics is a peer-reviewed open acess journal that publishes original research articles as well as review articles in all areas of Oncology. this practical journal also includes information on new products, new therapies and patient management, as well as reviews of the latest research. Cancer is a complex problem. The international effort to understand and control it involves clinicians trained in many branches of medicine and scientists from most biological disciplines, chemistry, pharmaceutical and physical sciences The International Online Journal of Cancer & Therapeutics exists to serve the needs of this diverse community, providing a forum for prompt communication of original and innovative research findings that have relevance to understanding the etiology of cancer and to improving the treatment and survival of patients.

The journal publishes important original studies, reviews, and perspectives within the major topic areas of biology of premalignancy, risk factors and risk assessment, early detection research, immunoprevention, and chemopreventive and other interventions, including the basic science behind them. This journal comprises preclinical, clinical and translational research, with special attention given to molecular discoveries and an emphasis on building a translational bridge between the basic and clinical sciences. Main focuses of interest include: systemic anticancer therapy (with specific interest on molecular targeted agents and new immune therapies), randomized trials (including negatives ones), top-level guidelines, and new fields currently emerging as key components of personalized medicine, such as molecular pathology, bioinformatics, modern statistics, and biotechnologies. Radiotherapy, surgery and pediatrics manuscripts can be considered if they display a clear interaction with one of the fields above or are paradigm-shifting.

Oncology is the diagnosis and treatment of cancers,including breast,prostate,colon,lung and ovarian cancers as well as brain tumors,leukemia,lymphoma and many other types of cancer.. A doctor who works in the field of oncology is called an oncologist. The primary regions of oncology are radiation, which is worried with radiation treatment, or radiotherapy; surgical, which is contained specialists who spend significant time in tumor evacuation; therapeutic, which manages disease drugs, including chemotherapy; and interventional, which includes interventional radiologists who have some expertise in insignificantly obtrusive picture guided tumor treatment.


committee

Members

ThumbnailImage

Charles Jeffrey Smith

Professor

 

 

 

 

 

 

 

Ph.D. in Chemistry : May, 1997 University of Missouri,Columbia, Missouri, 65211

                                  Dissertation Advisors:  Kattesh V. Katti and Richard Thompson

                                  Dissertation Title: “Transition Metal Complexes of Novel,                                                 Polydentate, Water-Soluble, Phosphine Ligands”

B.S. in Chemistry : May, 1992 Missouri State University, Springfield, Missouri,                                                     65897, Advisors: Robert Ernst and Tamara Jahnke

                             

  • Charles Jeffrey Smith, Recipient of Stache Dash 5k Award. Traditions Committee for the University of Missouri Student Union, Columbia, MO, November 12, 2017.
  • Charles Jeffrey Smith, Chairperson, BLR&D Field-Based Planning Meeting: “Development of Radiopharmaceuticals for Cancer and Bone Diseases: A Pipeline from the Bench to the Clinic”. United States Department of Veterans’ Affairs, Los Angeles, CA, July 17, 2017.
  • Charles Jeffrey Smith, Chairperson, 1st Research Coordination Meeting on “Cu-64 Radiopharmaceuticals for Theranostic Applications”. International Atomic Energy Agency, Vienna, Austria, November 7-12, 2016.
  • Charles Jeffrey Smith, Selection to the Order of Socrates II for Excellence in Medical Education. University of Missouri School of Medicine, Office of Medical Education, Columbia, MO, June 30, 2009.
  • Charles Jeffrey Smith, Nomination for Gold Chalk Award. University of Missouri Graduate Professional Council, Columbia, MO, 2008.
  • Charles Jeffrey Smith, Who’s Who in America, 2006/2007.
  • Charles Jeffrey Smith, Special Emphasis Panel National Institute of Health.  National Institute of Allergy & Infectious Diseases.  “Radionuclide Decorporation Agents for Radiation/Nuclear Emergencies:  Project Bioshield.”  RFA-A1-06-030, 2006.
  • Charles Jeffrey Smith, Full Member in Sigma Xi (The Scientific Research Honor Society), 2006-present.
  • Charles Jeffrey Smith, United States Army Honorable Discharge, 1992.
  • Charles Jeffrey Smith, United States Air Force Mathematics and Science Award, 1987.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  1. Xu, H.; Miao, Y.; Bandari, R.P.; Lee, L.; Yu, P.; Smith, C.J.; and Ma, L. “Synthesis, Characterization, and In Vivo Near-Infrared Fluorescence Imaging of Bombesin Antagonists Targeting GRP Receptors in Prostate Cancer.” J. Med. Chem., 2018, In Preparation.
  2. Bandara, N.; Stott Reynolds, T.; Schehr, R.; Diebolder, P.J.; Krieger, S.; Xu, J.; Miao, Y.; Rogers, B.E.; and Smith, C.J. “DOTA-conjugated RGD/Bombesin Antagonist as a Potential Theranostic Agent for Prostate Cancer Using a True Matched-pair 90Y/86Y-labeled Bivalent Ligand, [RGD-Glu-(DO3A)-6-Ahx-RM2].” Nucl. Med. Biol., 2018, In Preparation.
  3. Bandari, R.P.; Lewis, M.R.; and Smith, C.J. “Synthesis and Evaluation of [DUPA-6-Ahx-Lys (DOTA)-6-Ahx-RM2}, a Novel, Bivalent Targeting Ligand for GRPR/PSMA Biomarkers of Prostate Cancer.” Chemical Biology LETTERS, 2018, 5(1), 11-24.
  4. Al-Yasiri, A.Y.; Khoobchandani, M.; Cutler, C.S.; Watkinson, L.; Carmack, T.; Smith, C.J.; Kuchuk, M.; Loyalka, S.K.; Lugao, A.B.; and Katti, K.V. “Mangiferin Functionalized Radioactive Gold Nanoparticles (MGF-198AuNPs) in Prostate Tumor Therapy: Green Nanotechnology of Production, In Vivo Tumor Retention, and Evaluation of Therapeutic Efficacy.” Dalton Trans., 2017, 46, 14561.
  5. Jiang, Z.; Bandari, R.P.; Reynolds, T.S.; Xu, J.; Miao, Y.; Rold, T.L.; Szczodroski, A.F.; Jurisson, S.S.; and Smith, C.J. “Molecular Imaging Investigations of a 68Ga/64Cu-labeled Bivalent Ligand, [RGD-Glu-(DO3A)-6-Ahx-RM2], Targeting GRPR/avb3 Biomarkers: a Comparative Study.” Radiochimica Acta, 2016, 104(7), 499-512.
  6. Liu, D.; Balkin, E.R.; Jia, F.; Ruthengael, V.C.; Smith, C.J.; and Lewis, M.R. “Targeted Antisense Radiotherapy and Dose Fractionation Using a 177Lu-labeled Anti-BCL2 Peptide Nucleic Acid-Peptide Conjugate.” Nucl. Med. Biol., 2015, 42, 704-710.
  7. Stott Reynolds, T.; Bandari, R.P.; Jiang, Z.; and Smith, C.J.; “Lutetium-177 Labelled Bombesin Peptides for Radionuclide Therapy.” Current Radiopharmaceuticals, 2015, 9(1), 33-43.
  8. Stott Reynolds, T.; Schehr, R.; Liu, D.; Xu, J.; Miao, Y.; Hoffman, T.J.: Rold, T.L.; Lewis, M.R.; and Smith, C.J.; “Characterization and Evaluation of a DOTA-conjugated Bombesin/RGD-Antagonists for Prostate Cancer Tumor Imaging and Therapy.” Nucl. Med. Biol., 2015, 42(2), 99-108.
  9. Smith, C.J. “Novel Agents for Molecular Imaging and Possible Therapy of Human Cancers.” Austin Journal of Nuclear Medicine and Radiotherapy, 2014, 1(2), 3.
  10. Suresh, D.; Zambre, A.; Chanda, N.; Hoffman, T.J.; Smith, C.J.; Robertson, D.J.; and Kannan, R. “Bombesin Peptide Conjugated Gold Nanocages Internalize via Clathrin Mediated Endocytosis.” Bioconjugate Chem., 2014, 25, 1565-1579.
  11. Bandari, R.P.; Jiang, Z.; Stott Reynolds, T.; Bernskoetter, N.E.; Connors, J.P.; Szczodroski, A.F.; Bassuner, K.J.; Kirkpatrick, D.L.; Rold, T.L.; Sieckman, G.L.; Hoffman, T.J.; and Smith, C.J. “Synthesis and Biological Evaluation of Copper-64 Radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a Novel Bivalent Targeting Vector Having Affinity for Two Distinct Biomarkers (GRPr/PSMA) of Prostate Cancer.” Nucl. Med. Biol., 2014, 41(4), 355-363.
  12. Durkan, K.; Jiang, Z.; Rold, T.L.; Sieckman, G.L.; Hoffman, T.J.; Bandari, R.J.; Szczodroski, A.F.; Liu, L.; Miao, Y.; Stott Reynolds, T.; and Smith, C.J.  “A Heterodimeric [64Cu-NO2A-RGD-Glu-6-Ahx-RM2] αvβ3/GRPr-targeting Antagonist Radiotracer for PET Imaging of Prostate Tumors.” Nucl. Med. Biol., 2014, 41(2), 133-139.
  13. Cai, Q-Y.; Yu, P.; Besch-Williford, C.; Smith, C.J.; Sieckman, G.; Hoffman, T.J.; and Ma, L. “Near-infrared Fluorescence Imaging of Gastrin Releasing Peptide Receptor Targeting in Prostate Cancer Lymph Node Metastases.” The Prostate, 2013, 73, 842-854.
  14. Wienhoff, B.E.; Prasanphanich, A.; Lane, S.R.; Nanda, P.K.; Sieckman, G.L.; and Smith, C.J. “Synthesis and Selective Radiolabeling Strategies for Production of [90Y-DOTA-64Cu-NOTA-8-Aoc-BBN(7-14)NH2] Conjugate; a Dual Negatron/Positron Emitting Radioligand.” Journal of Synthesis and Reactivity in Inorganic, Metal-Organic, and Nano-metal Compounds, 2013, 43(2), 178-184.
  15. Nanda, P.K.; Rold, T.L.; Sieckman, G.L.; Szczodroski, A.F.; Hoffman, T.J.; Rogers, B.E.; Wienhoff, B.E.; and Smith, C.J. “ Positron-emission Tomography (PET) Imaging Agents for Diagnosis of Human Prostate Cancer: Agonist Versus Antagonist Ligands.” In Vivo. International Journal of Experimental and Clinical Pathophysiology and Drug Research, 2012, 26, 583-592.
  16. Shukla, R.; Nripen, C.; Zambre, A.; Katti, K.; Upendran, A.; Kulkarni, R.R.; Nune, S.; Casteel, S.W.; Smith, C.J.; Boote, E.; Robertson, J.D.; Kan, P.; Engelbrecht, H.; Watkinson, L.D.; Carmack, T.L.; Lever, J.R.; Cutler, C.; Caldwell, C.; Kannan, R.; and Katti, K.V. “Laminin Receptor Specific Gold Nanoparticles (198AuNP-EGCg) Show Efficacy in Treating Prostate Cancer.” Proceedings of the National Academy of Sciences USA, 2012, 109(31), 12426-12431.
  17. Dijkgraaf, I.; Franssen, G.M.; McBride, W.J.; D’Souza, C.A.; Smith, C.J.; Goldenberg, D.M.; Oyen, W.J.G.; and Boerman, O.C. “PET Imaging of GRPR-expressing Tumors With an 18F-labeled Bombesin Analog.” J. Nucl. Med., 2012, 53(6), 947-952.
  18. Nanda, P.K.; Pandey, U.; Bottenus, B.N.; Rold, T.L.; Sieckman, G.L.; Hoffman, T.J.; and Smith, C.J. “Bombesin Analogues for Gastrin-releasing Peptide Receptor Imaging.” Nucl. Med. Biol., 2012, 39, 461-471.
  19. Jackson, A.B.; Nanda, P.K.; Rold, T.L.; Sieckman, G.L.; Szczodroski, A.F.; Hoffman, T.J.; Chen, X.; and Smith, C.J. “64Cu-NO2A-RGD-Glu-6-Ahx-BBN(7-14)NH2: A Heterodimeric Targeting Vector for Positron-emission Tomography Imaging of Prostate Cancer.” Nucl. Med. Biol., 2012, 39, 377-387.
  20. Oliveira, E.A.; Faintuch, B.L.; Nunez, E.G.F.; Moro, A.M.; Nanda, P.K.; and Smith, C.J. “Radiotracers for Different Angiogenesis Receptors in a Melanoma Model.” Melanoma Research, 2012, 22(1), 45-53.
  21. Faintuch, B.L.; Oliveira, E.A.; Fernandez, E.G.; Teodoro, R.; Moro, A.M.; Nanda, P.K.; and Smith, C.J. “Comparison of Two Peptide Radiotracers for Prostate Carcinoma Targeting.” Clinics, 2012, 67(2), 163-170.
  22. Cutler, C.S.; Sisay, N.; Cantorias, M.; Galazzi, F.; Quinn, T.P.; and Smith, C.J. “Development of PET Molecular Targeting Agents with Gallium-68”. Radiochimica Acta, 2011, 99, 641-651.
  23. Esteves, T.; Marques, F.; Paulo, A.; Rino, J.; Nanda, P.; Smith, C.J.; and Santos, I. “Multifunctional Tricarbonyl M(I) (M = Re, 99mTc) Complexes Bearing an Acridine Orange Intercalator and Bombesin Analogues: Synthesis, Characterization, and Cell Studies.” Journal of Biological Inorganic Chemistry, 2011, 16(8), 1141-1153.
  24. Kannan, R.; Pillarsetty, N.; Gali, H.; Hoffman, T.J.; Volkert, W.A.; Barnes, C.L.; Jurisson, S.S.; Smith, C.J.; and Katti, K.V. “Design and Synthesis of a Bombesin Peptide-Conjugated Tripodal Phosphino Dithioether Ligand Topology for the Stabilization of fac-[M(CO)3]+ Core (M = 99mTc or Re).” Inorg. Chem., 2011, 50, 6210-6219.
  25. Chandra, N.; Kattumuri, V.; Shukla, R.; Zambre, A.; Katti, K.; Upendran, A.; Kulkarni, R.; Kan, P.; Fent, G.; Casteel, S.; Smith, C.J.; Boote, E.; Robertson, J.D.; Cutler, C.; Katti, K.; and Kannan, R. “Bombesin Functionalized Gold Nanoparticles Show In Vitro and In Vivo Cancer Receptor Specificity.” Proceedings of the National Academy of Sciences USA, 2010, 107(19), 8760-8765.
  26. Lane, S.R.; Nanda, P.K.; Rold, T.L.; Sieckman, G.L.; Figueroa, S.D.; Hoffman, T.J.; Jurisson, S.S.; and Smith, C.J.  “Optimization, Biological Evaluation, and MicroPET Imaging of Copper-64-Labeled Agonists, [64Cu-NO2A-X-BBN(7-14)NH2], in a Prostate Tumor Xenografted Mouse Model.” Nucl. Med. Biol., 2010, 37, 751-761.
  27. Liu, D.; Overbey, D.; Watkinson, L.D.; Smith, C.J.; Figueroa, S.D.; Hoffman, T.J.; Forte, L.R.; Volkert, W.A.; and Giblin, M.F. “Comparative Evaluation of 64Cu-labeled E. Coli Heat-stable Enterotoxin Analogs for PET Imaging of Colorectal Cancer.” Bioconjugate Chem., 2010, 21, 1171-1176.
  28. Chanda, N.; Kan, P.: Watkinson, L.D.; Shukla, R.; Zambre, A.; Carmack, T.L.; Engelbrecht, H.; Lever, J.R.; Katti, K.; Fent, G.M.; Casteel, S.W.; Smith, C.J.; Miller, W.H.; Jurisson, S.; Boote, E.; Robertson, J.D.; Cutler, C.; Dobrovolskaia, M.; Kannan, R.; Katti, K.V. “Radioactive Gold Nanoparticles in Cancer Therapy: Therapeutic Efficacy Studies of 198AuNP-GA Nanoconstruct in Prostate Tumor Bearing Mice.” Nanomedicine: Nanotechnology, Biology, and Medicine, 2010, 6(2), 201-209.
  29. Retzloff, L.B.; Heinzke, L.; Figureoa, S.D.; Sublett, S.V.; Sieckman, G.L.; Rold, T.L.; Hoffman, T.J.; and Smith, C.J. “Evaluation of [99mTc-(CO)3-X-Y-Bombesin(7-14)NH2] Conjugates for Targeting Gastrin Releasing Peptide Receptors Over-expressed on Breast Carcinoma.” Anticancer Research, 2010, 30(1), 19-30.
  30. Nanda, P.K.; Lane, S.R.; Retzloff, L.B.; Pandey, U.S.; and Smith, C.J. “Radiolabeled Regulatory Peptides for Imaging and Therapy.” Current Opinion in Endocrinology and Diabetes, 2010, 17, 69-76.
  31. Hoffman, T.J.; and Smith, C.J. “True Radiotracers: Copper-64 Targeting Vectors Based Upon Bombesin Peptide.” Nucl. Med. Biol., 2009, 36, 579-585.
  32. Prasanphanich, A.; Retzloff, L.; Lane, S.R.; Nanda, P.K.; Sieckman, G.L.; Rold, T.L.; Ma, L.; Figueroa, S.D.; Sublett, S.V.; Hoffman, T.J.; and Smith, C.J. “In Vitro and In Vivo Analysis of [64Cu-NOTA-8-Aoc-BBN(7-14)NH2]: a Site-Directed Radiopharmaceutical for PET Imaging of T-47D Human Breast Cancer Tumors.” Nucl. Med. Biol., 2009, 36(2), 171-181.
  33. Faintuch, B.L.; Teodoro, R.; Duatti, A.; Morganti, L.; Muramoto, E.; Faintuch, S.; and Smith, C.J. “Radiolabeled Bombesin Analogs for Prostate Cancer Diagnosis: Preclinical Studies.” Nucl. Med. Biol., 2008, 35, 401-411.
  34. Lane, S.R.; Veerendra, B.; Rold, T.L.; Sieckman, G.L.; Hoffman, T.J.; Jurisson, S.S.; and Smith, C.J. “99mTc(CO)3-DTMA (DTMA = DIETHYLENETRIAMINE MONOACETATE) Bombesin Conjugates Having High Affinity for the GRP Receptor.” Nucl. Med. Biol., 2008, 35(3), 263-272.
  35. Prasanphanich, A.; Nanda, P.K.; Rold, T.L.; Ma, L.; Lewis, M.R.; Hoffman, T.J.; Sieckman, G.L.; Figueroa, S.D.; and Smith, C.J. “[64Cu-NOTA-8-Aoc-BBN(7-14)NH2] Conjugate: A Novel Targeting Vector for Positron Emission Tomographic Imaging of Gastrin Releasing Peptide Receptor-Expressing Tissues.” The Proceedings of the National Academy of Sciences USA, 2007, 104(30), 12462-12467.
  36. Kunstler, J-U.; Veerendra, B.; Figueroa, S.D.; Sieckman, G.L.; Rold, T.L.; Hoffman, T.J.; Smith, C.J.; and Pietzsch, H.J. “Organometallic 99mTc(III) 4+1 Bombesin(7-14)NH2 Conjugates: Synthesis, Radiolabeling, and In Vitro/In Vivo Studies.” Bioconjugate Chem., 2007, 18, 1651-1661. 
  37. Ma, L.; Yu, P.; Veerendra, B.; Rold, T.L.; Retzloff, L.; Prasanphanich, A.; Sieckman, G.; Hoffman, T.J.; Volkert, W.A.; and Smith, C.J.  “In Vitro and In Vivo Evaluation of Alexa Fluor 680-BBN[7-14]NH2 Peptide Conjugate; A High-affinity Fluorescent Probe Having High Selectivity for the GRP Receptor.” Molecular Imaging, 2007,6(3), 171-180.
  38. Alves, S.; Correia, J.D.G.; Rold, T.L.; Prasanphanich, A.; Haubner, R.; Rupprich, M.; von Guggenberg, E.; Alberto, R.; Decristoforo, C.; Santos, I.; and Smith, C.J.  “99mTc(CO)3-Pyrazolyl Conjugates of RGD:  In Vitro and In Vivo Evaluation of [99mTcL(CO)3-Cyclo[Arg-Gly-Asp-D-Tyr-Lys]] (L = A Tridentate Pyrazolyl-based Chelating Ligand Framework).” Bioconjugate Chem., 2007, 18, 530-537.
  39. Prasanphanich, A.; Lane, S.R.; Figueroa, S.D.; Ma, L.; Rold, T.L.; Sieckman, G.L.; Hoffman, T.J.; McCrate, J.M.; and Smith, C.J. “The Effects of Linking Substituents on the In Vivo Behavior of Site-directed, Peptide-based, Diagnostic Radiopharmaceuticals.” In Vivo. International Journal of Experimental and Clinical Pathophysiology and Drug Research, 2007, 21(2), 3-18.
  40. Decristoforo, C.; Santos, I.; Pietzsch, H.J.; Duatti, A.; Smith, C.J.; Faintuch, B.L.; Rey, A.; Alberto, R.; von Guggenberg, E.; and Haubner, R.  “Comparison of In Vitro and In Vivo Properties of 99mTc-RGD Peptides Labeled Using Different Novel Tc-cores.” The Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2007, 51(1), 33-41.
  41. Kannan, R.; Rahing, V.; Cutler, C.; Pandrapragada, R.; Katti, K.V.; Kattumuri, V.; Robertson, J.D.; Casteel, S.J.; Jurisson, S.; Smith, C.; Boote, E.; and Katti, K.V. “Nanocompatible Chemistry Toward Fabrication of Target-Specific Gold Nanoparticles.” Journal of the American Chemical Society, 2006, 128(35), 11342-11343.
  42. Veerendra, B.; Sieckman, G.L.; Hoffman, T.J.; Rold, T.; Retzloff, L.; McCrate, J.; Prasanphanich, A.; and Smith C.J.  “Synthesis, Radiolabeling and In vitro GRP Receptor Targeting Studies of 99mTc-Triaza-X-BBN[7-14]NH2 (X = Serylserylserine, Glycylglycylglycine, Glycylserylglycine, or Beta Alanine).”  Journal of Synthesis and Reactivity in Inorganic, Metal-Organic, and Nano-metal Compounds, 2006, 36(6), 481-491.
  43. Johnson, C.V.; Shelton, T.D; Smith,C.J.; Ma, L.; Perry, M.C.; Volkert, W.A.; and Hoffman, T.J.  “Evaluation of Combined 177Lu-DOTA-8-AOC-BBN(7-14)NH2 GRP Receptor Targeted Radiotherapy and Chemotherapy in PC-3 Human Prostate Tumor Cell Xenografted SCID Mice.” Cancer Biotherapy & Radiopharmaceuticals, 2006, 21(2), 155-165.
  44. Moustapha, M.E.; Ehrhardt, G.J.; Smith, C.J.; Szajek, L.; Eckelman, W.C.; and Jurisson, S.J.  “Preparation of Cyclotron-Produced Re-186 and Comparison with Reactor-Produced Re-186 and Generator-Produced Re-188 for the Labeling of Bombesin.” Nucl. Med. Biol., 2006, 33(1), 81-89.
  45. Alves, S.; Santos, I.; Bhadrasetty, V.; Correia, J.D.G.; Sieckman, G.L.; Hoffman, T.J.; Rold, T.; Figueroa, S.D.; Retzloff, L.; McCrate, J.; Prasanphanich, A.; and Smith, C.J.   “Pyrazolyl Conjugates of Bombesin:  A New Tridentate Ligand Framework for Stabilization of the fac-MI(CO)3 Moiety.” Nucl. Med. Biol., 2006, 33(5), 625-634.
  46. Smith, C.J.; Volkert, W.A.; and Hoffman, T.J.  “Radiolabeled Peptide Conjugates for Targeting of the Bombesin Receptor Superfamily Subtype.”  Nucl. Med. Biol., 2005, 32(7), 733-740.
  47. Alves, S.; Paulo, A.; Correia, J.D.G.; Gano, L.; Smith, C.J.; and Santos, I. Pyrazolyl Derivatives as Bifunctional Chelators for Labeling Tumor-Seeking Peptides with the fac-[M(CO)3]+ Moiety (M = 99mTc, Re): Synthesis, Characterization, and Biological Behavior.”  Bioconjugate Chem., 2005, 16(2), 438-449.
  48. Giblin, M.F.; Veerendra, B.; and Smith, C.J. “Radiometallation of Receptor-Specific Peptides for Diagnosis and Treatment of Human Cancer.” In Vivo. New Anticancer Agents: In Vitro and In Vivo Evaluation (First Special Edition/Anticancer Research), 2005, 19, 9-30.
  49. Faintuch B.L.; Santos R.L.S.R.; Souza A.L.F.M.; Hoffman T.J.; Greeley M.; and Smith C.J.  “99mTc-HYNIC-Bombesin (7-14)NH2: Radiochemical Evaluation With Co-ligands EDDA (EDDA = Ethylenediamine-N,N’-diacetic Acid), Tricine, and Nicotinic Acid.” Journal of Synthesis and Reactivity in Inorganic, Metal-Organic, and Nano-metal Compounds, 2005, 35, 43-51.
  50. Miller, W.H.; Hartmann-Siantar, C.; Fisher, D.; Descalle, M-A.; Daly, T.; Lehmann, J.; Lewis, M.R.; Hoffman, T.J.; Smith, C.J.; Situ, P.D.; and Volkert, W.A.  “Evaluation of Beta Absorbed Fractions in a Mouse Model for 90Y, 188Re, 166Ho, 149Pm, 177Lu, and 64Cu Radioisotopes.” Cancer Biotherapy & Radiopharmaceuticals, 2005, 20(4) 436-449.
  51. Smith, C.J.; Volkert, W.A.; and Hoffman, T.J.  “Gastrin Releasing Peptide (GRP) Receptor-Targeted Radiopharmaceuticals:  A Concise Update.”  Nucl. Med. Biol., 2003, 30, 861-868.
  52. Ketring, A.R.; Ehrhardt, G.J.; Embree, M.F.; Bailey, K.D.; Tyler, T.T.; Gawenis, J.A.; Jurisson, S.S.; Engelbrecht, H.P.; Smith, C.J.; and Cutler, C.S.  “Production and Supply of High Specific Activity Radioisotopes for Radiotherapy Applications.”  Alasbimn Journal, 2003, 5(19), 1-7.
  53. Smith, C.J.; Sieckman, G.L.; Owen, N.K.; Hayes, D.L.; Mazuru, D.L.; Volkert, W.A.; and Hoffman, T.J.  “Radiochemical Investigations of [188Re(H2O)(CO)3-Dpr-SSS-Bombesin(7-14)NH2]:  Syntheses, Radiolabeling, and In Vitro/In Vivo Studies Where Dpr = Diaminopropionic Acid.” Anticancer Research, 2003, 23(2), 63-70.
  54. Hoffman, T.J.; Gali, H.; Smith, C.J.; Sieckman, G.L.; Hayes, D.L.; Owen, N.K.; and Volkert, W.A.;  “Novel Series of Indium-111 Labeled Bombesin Analogues as Potential Radiopharmaceuticals for Specific Targeting of Gastrin Releasing Peptide (GRP) Receptors Expressed on Human Prostate Cancer Cells.” J. Nucl. Med., 2003, 44, 823-831.
  55. Smith, C.J.; Sieckman, G.L.; Owen, N.K.; Hayes, D.L.; Mazuru, D.G.; Kannan, R.; Volkert, W.A.; and Hoffman, T.J.  “Radiochemical Investigations of GRP Receptor-specific [99mTc(X)(CO)3- Dpr-Ser-Ser-Ser-Gln-Trp-Ala-Val-Gly-His-Leu-Met-(NH2)] in PC-3, Tumor-bearing, Rodent Models:  Syntheses, Radiolabeling, and In Vitro/In Vivo Studies Where Dpr = 2,3-Diaminopropionic acid and X = H2O or P(CH2OH)3.”  Cancer Research, 2003, 63, 4082-4088.
  56. Smith, C.J.; Gali, H.; Sieckman, G.L.; Hayes, D.L.; Owen, N.K.; Mazuru, D.G.; Volkert, W.A.; and Hoffman, T.J.  “Radiochemical Investigations of 177Lu-DOTA-8-BBN[7-14]NH2:  An In Vitro/In Vivo Assessment of the Targeting Ability of this New Radiopharmaceutical for PC-3 Human Prostate Cancer Cells.” Nucl. Med. Biol., 2003, 30(3), 101-109.
  57. Smith, C.J.; Gali, H.; Sieckman, G.L.; Higginbotham, C.; Volkert, W.A.; and Hoffman, T.J.  “Radiochemical Investigations of 99mTc-N3S-X-BBN(7-14)NH2:  An In Vitro/In Vivo Structure-Activity Relationship Study Where X = 0, 3, 5, 8, and 11-Carbon Tethering Moieties.” Bioconjugate Chem., 2003, 14, 93-102.
  58. Li, W.P.; Smith, C.J.; Cutler, C.S.; Ketring, A.R; and Jurisson, S.S.  “Aminocarboxylate and Octreotide Complexes with No Carrier Added 177Lu, 166Ho, and 149Pm.”  Nucl. Med. Biol., 2003, 30, 241-251.
  59. Cutler, C.S.; Smith, C.J.; Ehrhardt, G.J.; Tyler, T.T.; Jurisson, S.S.; and Deutsch, E.  “Current and Potential Therapeutic Uses of Lanthanide Radioisotopes.” Cancer Biotherapy & Radiopharmaceuticals, 2000, 15(6), 531.
  60. Katti, K.V.; Gali, H.; Smith, C.J.; and Berning, D.E.  “Design and Development of Functionalized Water-Soluble Phosphines:  Catalytic and Biomedical Implications.”  Acc. Chem. Res., 1999, 32, 9.
  61. Smith, C. J.; Reddy, V. S.; and Katti, K. V.  “Different Coordination Modes of the New Water-Soluble Triphosphine (PhP[CH2CH2P(CH2OH)2]2) with Pt(II), Pd(II), Rh(I), and Re(V).” (FULL PAPER) J. Chem. Soc., Dalton Trans., 1998, 8, 1365.
  62. Smith, C.J.; Li, N.; Katti, K.V.; Volkert, W.A.; and Ketring, A.R.  “In Vitro and In Vivo Characterization of Novel, Water - Soluble, Dithio-bisphosphine 99mTc-Complexes.”  Nucl. Med. Biol.  1997, 24, 685.
  63. Smith, C.J.; Katti, K.V; Volkert, W.A.; and Barbour, L.J.  “The Synthesis and Characterization of Chemically Flexible Water - Soluble Dithio–Bisphosphine Compounds: (HOH2C)2P(CH2)2S-(CH2)3S(CH2)2P(CH2OH)2, (HOH2C)2P(CH2)2-S(CH2)3S(CH2)2P(CH2OH)2, and (HOH2C)2P(CH2)2S(CH2)3S(CH2)2P(CH2OH)2.   Systematic Investigation of the Effect of Chain Length on the Coordination Chemistry of Rhenium(V). X-Ray Crystal Structures of [ReO2(HOH2C)2P(CH2)2S(CH2)3S-(CH2)2P(CH2OH)2]2(Cl)2, [ReO2(HOH2C)2P(CH2)2S(CH2)4S-(CH2)2P(CH2OH)2]2(ReO4-)2, [ReO2(HOH2C)2P(CH2)3S(CH2)3S(CH2)3P(CH2OH)2](Cl).”  Inorg. Chem.  1997, 36, 3928.
  64. Smith, C.J.; Reddy, V.S.; Katti, K.V.; and Barbour, L.J.  “The Synthesis and Coordination Chemistry of the First Water - Soluble Dithio-Bisphosphine Ligands [(HOH2C)2P(CH2)2S-X-S(CH2)2P(CH2OH)2] (X = (CH2)3 or C6H4).  X-Ray Crystal Structure of [Pd(HOH2C)2P(CH2)2S(CH2)3S(CH2)2P(CH2OH)2](Cl)2.” Inorg. Chem.  1997, 36, 1786.
  65. Smith, C.J.; Reddy, V.S.; and Katti, K.V.  “New Advances in the Synthesis of a Water-Soluble Triphosphine and the Development of Tripodally Coordinated Rhodium(I) and Platinum(II) Complexes.” J. Chem. Soc., Chem. Commun.  1996, 2557.